Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs

Vaccine

Volumn 31, Issue 34, 2013, Pages 3435-3441

  Kommareddy, S ^a   Baudner, B C ^b   Bonificio, A ^a   Gallorini, S ^b   Palladino, G ^a   Determan, A S ^c   Dohmeier, D M ^c   Kroells, K D ^c   Sternjohn, J R ^c   Singh, M ^a   Dormitzer, P R ^a   Hansen, K J ^c   O'Hagan, D T ^a  

^a Novartis Vaccines and Diagnostic   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c 3M COMPANY   (United States)

Author keywords

Influenza vaccine; Intradermal; Microneedles

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG SYNTHESIS; FREEZE THAWING; GUINEA PIG; IMMUNE RESPONSE; IMMUNODIFFUSION; IMMUNOGENICITY; INFLUENZA VACCINATION; MICRONEEDLE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; TRANSDERMAL PATCH;

INFLUENZA VACCINE; INTRADERMAL; MICRONEEDLES;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DRUG STABILITY; FEMALE; GUINEA PIGS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; REPRODUCIBILITY OF RESULTS; TRANSDERMAL PATCH; VACCINATION; VACCINES, SUBUNIT;

EID: 84880510923     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.050     Document Type: Article

References (32)

1. Akazawa M., Sindelar J.L., Paltiel A.D. Economic costs of influenza-related work absenteeism. Value Health 2003, 6:107-115.
2. Meltzer M.I., Cox N.J., Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5:659-671.
3. WHO WHO Media Centre Influenza Fact Sheet 2009, http://www.who.int/mediacentre/factsheets/fs211/en/.
4. Hale B.G., Albrecht R.A., Garcia-Sastre A. Innate immune evasion strategies of influenza viruses. Future Microbiol 2010, 5:23-41.
5. Amorij J.P., Hinrichs W., Frijlink H.W., Wilschut J.C., Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010, 10:699-711.
6. Dormitzer P., Tsai T., Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012, 8:45-58.
7. O'Hagan D.T., Rappuoli R., De Gregorio E., Tsai T., Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011, 10:447-462.
8. Vogel F.R., Caillet C., Kusters I.C., Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 2009, 8:483-492.
9. Belshe R., Lee M.S., Walker R.E., Stoddard J., Mendelman P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004, 3:643-654.
10. Young F., Marra F. A systematic review of intradermal influenza vaccines. Vaccine 2011, 29:8788-8801.
11. Gill H.S., Prausnitz M.R. Coated microneedles for transdermal delivery. J Control Release 2007, 117:227-237.
12. Sullivan S.P., Koutsonanos D.G., Del Pilar Martin M., Lee J.W., Zarnitsyn V., Choi S.O., et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010, 16:915-920.
13. Zhu Q., Zarnitsyn V.G., Ye L., Wen Z., Gao Y., Pan L., et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A 2009, 106:7968-7973.
14. Kommareddy S., Baudner B.C., Oh S., Kwon S.Y., Singh M., O'Hagan D.T. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci 2012, 101:1021-1027.
15. Raphael A.P., Prow T.W., Crichton M.L., Chen X., Fernando G.J., Kendall M.A. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small 2010, 6:1785-1793.
16. Roxhed N., Samel B., Nordquist L., Griss P., Stemme G. Painless drug delivery through microneedle-based transdermal patches featuring active infusion. IEEE Trans Biomed Eng 2008, 55:1063-1071.
17. Tuft L., Yagle E.M., Rogers S. Comparative study of antibody response after various methods of administration of mixed typhoid vaccine with particular reference to intradermal and oral methods. J Infect Dis 1932, 50:98-110.
18. Choi H.J., Yoo D.G., Bondy B.J., Quan F.S., Compans R.W., Kang S.M., et al. Stability of influenza vaccine coated onto microneedles. Biomaterials 2012, 33:3756-3769.
19. Birchall J.C., Clemo R., Anstey A., John D.N. Microneedles in clinical practice-an exploratory study into the opinions of healthcare professionals and the public. Pharm Res 2011, 28:95-106.
20. Gupta J., Felner E.I., Prausnitz M.R. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther 2009, 11:329-337.
21. Koutsonanos D.G., Vassilieva E.V., Stavropoulou A., Zarnitsyn V.G., Esser E.S., Taherbhai M.T., et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2012, 2:357.
22. Weldon W.C., Martin M.P., Zarnitsyn V., Wang B., Koutsonanos D., Skountzou I., et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol 2011, 18:647-654.
23. Zhang Y., Brown K., Siebenaler K., Determan A., Dohmeier D., Hansen K. Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm Res 2012, 29:170-177.
24. Kommareddy S., Bonificio A., Gallorini S., Baudner B., Singh M., O'Hagan D. Preparation of highly concentrated influenza vaccine for use in novel delivery approaches. J Pharm Sci 2013, 102:866-875.
25. Schild G.C., Wood J.M., Newman R.W. A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 1975, 52:223-231.
26. Kapteyn J.C., Saidi M.D., Dijkstra R., Kars C., Tjon J.C., Weverling G.J., et al. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine 2006, 24:3137-3144.
27. Stohr K., Bucher D., Colgate T., Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol Biol 2012, 865:147-162.
28. Kim Y.C., Quan F.S., Compans R.W., Kang S.M., Prausnitz M.R. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release 2010, 142:187-195.
29. Kim Y.C., Quan F.S., Compans R.W., Kang S.M., Prausnitz M.R. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res 2011, 28:135-144.
30. Koutsonanos D.G., del Pilar Martin M., Zarnitsyn V.G., Jacob J., Prausnitz M.R., Compans R.W., et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 2011, 204:582-591.
31. Fernando G.J., Chen X., Primiero C.A., Yukiko S.R., Fairmaid E.J., Corbett H.J., et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J Control Release 2012, 159:215-221.
32. Barbero A.M., Frasch H.F. Pig and guinea pig skin as surrogates for human in vitro penetration studies: a quantitative review. Toxicol in Vitro 2009, 23:1-13.